BIOFILCHEM
Biofil Chemicals and Pharmaceuticals Limited
Healthcare · Drug Manufacturers - Specialty & Generic
Market price data is delayed by at least 15 minutes. Not for trading or investment decisions.
Fundamentals
Current Price
₹33.18
P/B Ratio
2.6
52W High
₹57.19
52W Low
₹25.6
Dividend Yield
—
Profit Margin
8.60%
ROE
—
Debt / Equity
0
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Peer Comparison same NSE industry · top 10 by 1M return
Pharmaceuticals Drugsas of 9 Apr 2026 close
| Symbol | Company | Price | P/B | RSI | 1M Ret | ROE | D/E |
|---|---|---|---|---|---|---|---|
| BIOFILCHEMyou | Biofil Chemicals & Pharmaceu | ₹33.18 | 2.60 | 60.9 | +8.0% | — | 0.00 |
| BETA | Beta Drugs Limited | ₹1,417 | 3.24 | 70.0 | +26.4% | — | 0.66 |
| VENUSREM | Venus Remedies Limited | ₹976.95 | 2.20 | 57.8 | +24.7% | — | 0.02 |
| BAFNAPH | Bafna Pharmaceuticals Limite | ₹136.13 | 3.53 | 69.0 | +23.8% | — | 0.36 |
| SHILPAMED | Shilpa Medicare Limited | ₹419 | 3.37 | 85.0 | +23.7% | — | 0.24 |
| KOPRAN | Kopran Limited | ₹156.02 | 1.50 | 75.0 | +23.7% | — | 0.31 |
| VALIANTORG | Valiant Organics Limited | ₹268.03 | 1.02 | 67.1 | +23.3% | — | 0.32 |
| SUVEN | Suven Life Sciences Limited | ₹177.98 | 14.06 | 77.2 | +23.2% | — | — |
| TAKE | Take Solutions Limited | ₹44.59 | 25.45 | 72.3 | +17.8% | — | — |
| NEULANDLAB | Neuland Laboratories Limited | ₹14,723 | 11.66 | 75.8 | +16.9% | — | 0.16 |
| BROOKS | Brooks Laboratories Limited | ₹71.57 | 1.82 | 63.2 | +14.6% | — | 0.07 |
Price Chart
Quarterly Results Last 4 quarters
| Metric | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|
| Revenue | ₹0.9 Cr | ₹13.5 Cr | ₹6.4 Cr | ₹8.4 Cr |
| Gross Profit | ₹0.4 Cr | ₹0.4 Cr | ₹0.4 Cr | ₹1.0 Cr |
| Operating Income | ₹0.0 Cr | ₹0.0 Cr | ₹-0.1 Cr | ₹0.0 Cr |
| Net Income | ₹0.1 Cr | ₹0.1 Cr | ₹2.4 Cr | ₹0.2 Cr |
Values in INR Crore. Source: yfinance / NSE filings.
SWOT Analysis AI · news + fundamentals
SWOT not available.
Recent News Sentiment
No recent news for this stock.
Data sourced from yfinance and public NSE filings. Not investment advice.